Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab to Start China Phase III Trial of Long-Acting Treatment for Dwarfism

publication date: Oct 2, 2020

Shanghai's I-Mab reported China approval to conduct a Phase III trial of eftansomatropin as a once-weekly treatment for growth hormone deficiency in pediatric patients (PGHD). Eftansomatropin uses Genexine's half-life extension hyFc® fusion technology for its long-acting delivery. Efficacy of weekly or biweekly dosing was comparable to the daily injected rhGH (genotropin). I-Mab acquired China rights to the candidate from Korea's Genexine. More details....

Stock Symbols: (NSDQ: IMAB) (KOSDAQ: 095700)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.